Latest news with #JPMorganHealthcareConference
Korea Herald
26-05-2025
- Business
- Korea Herald
Samsung Biologics hits W3tr in cumulative orders this year
Samsung Biologics, the biotech arm of Samsung Group, reported Monday that it has surpassed 3 trillion won ($2.2 billion) in cumulative contract orders for 2025, just five months into the year, following a series of major deals with global pharmaceutical firms. According to a regulatory filing, the company recently signed two new contract manufacturing organization, or CMO, deals totaling 440.5 billion won with pharmaceutical companies based in Europe and Asia. These contracts run through December 2030 and December 2033, respectively. Due to non-disclosure agreements, client names and product details were not disclosed. So far in 2025, Samsung Biologics has signed four CMO deals across the US, Europe and Asia. This achievement represents over 60 percent of its total contract value for 2024, reinforcing the company's global competitiveness. The company now counts 17 of the world's top 20 pharmaceutical companies as clients and has accumulated total orders of approximately $18.2 billion since its founding. With the recent launch of its fifth plant in April, adding 180,000 liters of capacity, Samsung Biologics has expanded its total capacity to 784,000 liters, the largest in the world. Samsung Biologics also maintains strong performance in quality control, recording a 99 percent batch success rate last year and securing 356 manufacturing approvals from global regulators as of April 2025. To expand its global presence, the company has actively participated in major industry events including JPMorgan Healthcare Conference, DCAT Week 2025 and PEGS Boston. Samsung Biologics will next join the BIO International Convention held in Boston this June to further strengthen its global partnerships.
Associated Press
31-03-2025
- Business
- Associated Press
Pain Neuromodulation Market to Reach $6.5 Billion by 2030
- The market includes spinal cord stimulation (SCS) systems as well as peripheral nerve stimulation (PNS) systems - SAN FRANCISCO, Calif., March 31, 2025 (SEND2PRESS NEWSWIRE) — Neurotech Reports, the publisher of the newsletter Neurotech Business Report, announced the availability of a new market research report that forecasts the growth of the worldwide market for implanted pain neuromodulation systems. According to the newly published report, ' The Market for Implanted Pain Neuromodulation Systems: 2025-2030,' the worldwide market will be $3.37 billion in 2025, growing to $6.49 billion by 2030, which represents a 12% compound annual growth rate. The market includes spinal cord stimulation (SCS) systems as well as peripheral nerve stimulation (PNS) systems. Neurotech Reports estimates that the PNS market will grow at a 29% CAGR between 2025 and 2030. Major players in the SCS market include Medtronic, Abbott, Boston Scientific, and Nevro, which was recently acquired by medtech manufacturer Globus Medical. The report includes Neurotech Reports editors' analysis of the impact of this transaction on the competitive landscape of the SCS market. Newer players in the SCS market include Saluda Medical, which pioneered the concept of closed-loop SCS, and European firm Biotronik. Leading competitors in the PNS space include Curonix, which markets an injectable pain stimulator, SPR, which markets a percutaneous system, Nalu Medical, Bioventus, and Mainstay Medical, which markets a restorative neuromodulation system for treatment of back pain of mechanical origin. Several startup and emerging firms are poised to enter the space in coming years. The Market for Implanted Pain Neuromodulation Systems: 2025-2030 was authored by the editors of Neurotech Reports, including James Cavuoto, Jeremy Koff, Victor Pikov, and others. Now in its 25th year of publishing, Neurotech Reports is the longest-serving publishing and market-intelligence firm serving the neuromodulation market. The report includes up-to-date information obtained at the 2025 meeting of the North American Neuromodulation Society, the 2025 JP Morgan Healthcare Conference, and other recent events. Data for the report was obtained from dozens of confidential interviews with key executives in the industry as well as numerous implanters of neuromodulation devices. 'There are a number of market research reports that claim to offer insight on the neuromodulation industry. But neuromodulation industry professionals should ask if they've ever seen the authors of those reports at key conferences such as NANS, INS, LSI. Neurotech Reports editors have been covering these events for 25 years and know the key players inside and out,' said James Cavuoto, editor and publisher of Neurotech Reports. 'This report draws on our 25 years of reporting on the neuromodulation industry.' Image caption: Neurotech Reports recently released its latest forecast on the growth of the market for implanted pain neuromodulation systems, which include spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS) systems. NEWS SOURCE: Neurotech Reports Keywords: Biotechnology, Neurotech Reports, Market for Implanted Pain Neuromodulation Systems, Neurotech Business Report, Medical technology, biotech, medical devices, neurology, pharmaceuticals, spinal cord stimulation, SAN FRANCISCO, Calif.
Yahoo
27-03-2025
- Business
- Yahoo
Zoetis' Stock Is About as Cheap as It's Ever Been. 1 Thing to Know Before You Buy.
Shares in animal pharmaceutical company Zoetis (NYSE: ZTS) have been under a cloud since the release of the company's fourth-quarter earnings report in mid-February. The Q4 numbers were fine, but the company's revenue guidance fell short of expectations. That said, a fair number of variables could influence Zoetis' revenue in 2025, and focusing just on revenue guidance might not be the best way to think about the stock. One major alternative consideration could end up providing an upside or downside to expectations. Management and investors know that competitors have new products entering the market in 2025. Indeed, on the earnings call, CFO Wetteny Joseph said the operational organic revenue growth forecast of 6% to 8% "included a range of assumptions for new market entrants and conditions across our business." However, it's unclear how successful the new entrants will be, or whether they will affect Zoetis more or less than management expects in its guidance. A second alternative consideration could provide an upside. According to Joseph, management's guidance "does not include products that have not yet been approved." However, during the JPMorgan Healthcare Conference in January, CEO Kristin Peck showed a chart indicating three expected pharmaceutical product approvals over the next 12 months, five over the next 12 months to 36 months, and seven over the next 36 months to 60 months. As such, there's potential for some contribution from products potentially approved in 2025. Indeed, Peck told conferencegoers: "We're also super excited that we're going to have at least one approval each year for [the] next several years that will drive significant growth for the company." The potential approvals do provide some upside to 2025 guidance. Thinking longer-term, they are what will drive growth at Zoetis. Management believes pharmaceutical products approved for chronic kidney disease (dogs) and oncology (dogs) could open up markets worth up to $5.7 billion. That's something to think about. Before you buy stock in Zoetis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Zoetis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $697,245!* Now, it's worth noting Stock Advisor's total average return is 845% — a market-crushing outperformance compared to 165% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of March 24, 2025 JPMorgan Chase is an advertising partner of Motley Fool Money. Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase and Zoetis. The Motley Fool has a disclosure policy. Zoetis' Stock Is About as Cheap as It's Ever Been. 1 Thing to Know Before You Buy. was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
24-02-2025
- Business
- Yahoo
Pfizer sets sights on Summit's bispecific in combo with its ADCs
Pfizer has signed a deal with Summit Therapeutics to assess the efficacy of Summit's Keytruda-challenging ivonescimab in combination with several of its antibody-drug conjugates (ADCs). Under the agreement, Summit will supply ivonescimab – an investigational PD-1/VEGF bispecific antibody – for the studies, while Pfizer will oversee study operations. Both companies will jointly supervise the trials and retain their respective product rights. The initiation of these studies is scheduled for mid-2025. Following the announcement, Summit's share price rose 2.6% at market open on 24 January. Shares in the company dropped soon after, however, on the back of increased net losses for 2024 reported on the same day. The planned studies will evaluate the combination of ivonescimab with Pfizer's vedotin-based ADCs in several solid tumour settings. ADCs have gained prominence in oncology, with numerous pharmaceutical companies pursuing collaborations and acquisitions to bolster their pipelines with the promising modality. Pfizer's portfolio includes multiple ADCs, supported by its acquisition of ADC-focused company Seagen in March 2023 for $43bn. Pfizer has made it clear that it is committed to advancing its oncology portfolio. At the JP Morgan Healthcare Conference last month, Pfizer CEO Albert Bourla highlighted oncology and metabolic diseases as key areas for innovation. Summit hit the headlines in September 2024 when it reported that ivonescimab significantly reduced the risk of disease progression or death by 49% compared to MSD's blockbuster Keytruda (pembrolizumab) in a Phase III trial involving patients with advanced non-small cell lung cancer (NSCLC). The trial, known as HARMONi-2 (NCT05499390), enrolled 398 patients in China with PD-L1-positive advanced NSCLC. Results demonstrated a median progression-free survival of 11.14 months for ivonescimab recipients versus 5.82 months for those on Keytruda. This marked the first instance of a therapy showing a statistically significant improvement over Keytruda in this patient population. Keytruda, a PD-1 checkpoint inhibitor, generated $29.5bn in 2024, as per MSD's financials. This revenue flow is expected to continue growing with GlobalData predicting that the blockbuster will pull in $34.9bn in 2028, the year in which key Keytruda patents are set to expire. Summit acquired rights to ivonescimab in December 2022 through a $500m agreement with China-based Akeso, covering territories including the US and Europe. If approved, the antibody could generate up to $1.2bn in sales in 2030, as per GlobalData analysis. GlobalData is the parent company of Pharmaceutical Technology. "Pfizer sets sights on Summit's bispecific in combo with its ADCs" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Reuters
05-02-2025
- Business
- Reuters
AstraZeneca shareholders say they need clarity on China investigations
LONDON, Feb 5 (Reuters) - AstraZeneca (AZN.L), opens new tab investors will look past another strong set of quarterly results on Thursday to focus on the main issue overhanging shares: an investigation of a top executive by authorities in China, one of its key markets. The group said on Oct. 31 that its China head Leon Wang, who also led its international business as an executive vice president, had been detained by the Chinese authorities. It said it did not know what the investigation was about. Unless the company discloses fresh information about the probe and arrest at the release of fourth-quarter results, investors are likely to resume selling the stock even though the company's drug pipeline is viewed as strong, four healthcare investors and four analysts told Reuters. "This blindsided the company," said AstraZeneca shareholder Lucy Coutts at investment firm JM Finn, noting the "void" of information about the probe. "We don't have visibility on how or when this will be resolved," said Redburn Atlantic analyst Simon Baker. "This is the focus at the moment. It shouldn't be, but it is." Wang's arrest was followed by other revelations, including that more than 100 former sales staff in China had been sentenced to jail time in a large and ongoing medical insurance fraud case. In November the company reported a third investigation in China involving two current and two former senior executives, relating to the import of AstraZeneca cancer drugs from Hong Kong. It said the probe targeted only the individuals, not the company. AstraZeneca declined to comment for this article ahead of results. China has long been a key market for the drugmaker, the crown jewel of its international business that accounted for 13% of total sales in 2023. The Anglo-Swedish group announced plans in 2023 to build a $450 million factory in China. It signed several licensing deals with Chinese companies that year, and bought a China-headquartered biotech company. Chief Financial Officer Aradhana Sarin told investors at the JPMorgan Healthcare Conference last month the company anticipates some revenue impact on its China business in the fourth quarter and into 2025. Investors are hoping for more information on Thursday. SMALL RECOVERY AstraZeneca shares have recovered after the initial news of Wang's detention wiped around $18 billion off their value. They are up about 2% since early November. In December, AstraZeneca replaced Wang with senior executive Iskra Reic as executive vice president for international, based in Shanghai. Several investors said it may be tough for an executive who does not speak Mandarin and has never lived in China to navigate such a complicated market at a very sensitive time. Barclays analysts said in a recent note they believe AstraZeneca may pay a penalty to resolve the Wang investigation. In 2014, British drugmaker GSK (GSK.L), opens new tab was fined nearly 300 million pounds ($372 million) by a Chinese court for bribery. "Whilst there could be some commercial impact coming from lack of promotion whilst the investigation is ongoing, we view this as digestible given the momentum elsewhere in the business," Barclays said. ($1 = 0.8054 pounds)
